Structure-activity relationships for 4-nitrobenzyl carbamates of 5-aminobenz[e]indoline minor groove alkylating agents as prodrugs for GDEPT in conjunction with E. coli nitroreductase

Journal of Medicinal Chemistry

Volumn 46, Issue 12, 2003, Pages 2456-2466

  Hay, Michael P ^a   Atwell, Graham J ^a   Wilson, William R ^a   Pullen, Susan M ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROBENZYLCARBAMATE DERIVATIVE; 5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 AMINOBENZ[E]INDOLINE; ALKYLATING AGENT; CARBAMIC ACID DERIVATIVE; NITROREDUCTASE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHINESE HAMSTER; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; DRUG STRUCTURE; ESCHERICHIA COLI; GENETIC TRANSFECTION; NONHUMAN; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARBAMATES; CELL LINE; CRICETINAE; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; ESCHERICHIA COLI; GENE THERAPY; HUMANS; INDOLES; KINETICS; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED C3H; MICE, NUDE; MODELS, MOLECULAR; NITROREDUCTASES; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0038101357     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0205191     Document Type: Article

References (39)

1. Xu, G.; McLeod, H. L. Strategies for enzyme/prodrug cancer therapy. Clin. Cancer Res. 2001, 7, 3314-3324.
2. Denny, W. A. Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotech. 2002, in press.
3. Denny, W. A.; Wilson, W. R.; Hay, M. P. Recent developments in the design of bioreductive drugs. Br. J. Cancer 1996, 74 (Supp. 27), 32-38.
4. Pope, I. M.; Poston, G. J.; Kinsella, A. R. The role of the bystander effect in suicide gene therapy. Eur. J. Cancer 1997, 33, 1005-1016.
5. Denny, W. A. Nitroreductase-based GDEPT. Curr. Pharm. Des. 2002, 8, 99-110.
6. Zenno, S.; Koike, H.; Tanokura, M.; Saigo, K. Gene cloning, purification, and characterization of NfsB, a minor oxygen- insensitive nitroreductase from Escherichia coli, similar in biochemical properties to Frase I, the major flavin reductase in Vibrio fischeri. J. Biochem. 1996, 120, 736-744.
7. Parkinson, G. N.; Skelly, J. V.; Neidle, S. Crystal structure of FMN-dependent nitroreductase from Escherichia coli B: a prodrug-activating enzyme. J. Med. Chem. 2000, 43, 3624-3631.
8. Knox, R. J.; Friedlos, F.; Marchbank, T.; Roberts, J. J. Bioactivation of CB 1954: reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand cross-linking species. Biochem. Pharmacol. 1991, 42, 1691-1697.
9. Anlezark, G. M.; Melton, R. G.; Sherwood, R. F.; Coles, B.; Friedlos, F.; Knox, R. J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). I. Purification and properties of a nitroreductase enzyme from Escherichia coli. A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 1992, 44, 2289-2295.
10. Green, N. K.; Young, D. J.; Neoptolemos, J. P.; Friedlos, F., Knox, R. J.; Springer, C. J. Anlezark, G. M.; Michael, N. P.; Melton, R. G.; Ford, M. J.; Young, L. S.; Kerr, D. J.; Searle, P. F. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther. 1997, 4, 229-238.
11. Friedlos, F.; Court, S.; Ford, M.; Denny, W. A.; Springer, C. J. Gene-directed enzyme prodrug therapy: quantitative bystander cytotoxicity and DNA damage induced by CB1954 in cells expressing bacterial nitroreductase. Gene Ther. 1998, 5, 105-112.
12. Chung-Faye, G.; Palmer, C.; Anderson, D.; Clark, J.; Downes, M.; Baddeley, J.; Hussain, S.; Murray, P. I.; Searle, P.; Seymour, L.; Harris, P. A.; Ferry, D.; Kerr D. J. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res. 2001, 7, 2662-2668.
13. Palmer, D. H.; Mautner, V.; Mirza, D.; Buckels, J.; Olliff, D.; Hull, D.; Mountain, A.; Harris, P.; Djeha, H.; Ellis, J.; Horne, M.; Hill, S.; Wrighton, C.; Searle, P. F.; Kerr, D. J.; Young, L. S.; James, N. D. Virus-Directed enzyme prodrug therapy (VDEPT): clinical trials with adenoviral nitroimidazole reductase (Ad-ntr). Br. J. Cancer 2002, 86 (Suppl 1), S30.
14. Anlezark, G. M.; Melton, R. G.; Sherwood, R. F.; Wilson, W. R.; Denny, W. A.; Palmer, B. D.; Knox, R. J.; Friedlos, F.; Williams, A. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem. Pharmacol. 1995, 50, 609-618.
15. Atwell, G. J.; Boyd, M.; Palmer, B. D.; Anderson, R. F.; Pullen, S. M.; Wilson, W. R.; Denny, W. A. Synthesis and evaluation of 4-substituted analogues of 5-[N,N-bis-(2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase. Anti-Cancer Drug Des. 1996, 11, 553-567.
16. Friedlos, F.; Denny, W. A.; Palmer, B. P.; Springer, C. J. Mustard Prodrugs for activation by Escherichia coli nitroreductase in Gene-Directed Enzyme Prodrug Therapy. J. Med. Chem. 1997, 40, 1270-1275.
17. Wilson, W. R.; Pullen, S. M.; Hogg, A.; Helsby, N. A.; Hicks, K. O.; Denny, W. A. Quantitation of bystander effects in nitrore-ductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 2002, 62, 1425-1432.
18. Carl, P. L.; Chakravarty, P. K.; Katzenellenbogen, J. A. A novel connector linkage applicable in prodrug design. J. Med. Chem. 1981, 24, 479-480.
19. Hay, M. P.; Sykes, B. M.; O'Connor, C. J.; Denny, W. A. Substituent effects on the kinetics of reductively initiated fragmentation of nitrobenzyl carbamates designed as triggers for bioreductive drugs. J. Chem. Soc., Perkin Trans. 1 1999, 2759-2770.
20. Sykes, B. M.; Hay, M. P.; Bohinc-Herceg, D.; Denny, W. A.; O'Connor, C. J. Leaving group effects in reductively initiated fragmentation of 4-nitrobenzylcarbamates. J. Chem. Soc., Perkin Trans. 1 2000, 1601-1608.
21. Mauger, A. B.; Burke, P. J.; Somani, H. H.; Friedlos, F.; Knox, R. J. Self-immolative prodrugs: candidates for Antibody-Directed Enzyme Prodrug Therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 1994, 37, 3452-3458.
22. Hay, M. P.; Wilson, W. R.; Denny, W. A. Nitrobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy (GDEPT). Bioorg. Med. Chem. Lett. 1999, 9, 3417-3422.
23. Sagnou, M. J.; Howard, P. W.; Gregson, S. J.; Eno-Amooquaye, E.; Burke, P. J.; Thurston, D. E. Design and synthesis of novel pyrrolobenzodiazepine (PBD) prodrugs for ADEPT and GDEPT. Bioorg. Med. Chem. Lett. 2000, 10, 2083-2086.
24. Lee, M.; Simpson, J. E., Jr.; Woo, S.; Kaenzig, C.; Anlezark, G. M.; Eno-Amooquaye, E.; Burke, P. J. Synthesis of an aminopropyl analogue of the experimental anticancer drug tallimustine, and activation of its 4-nitrobenzylcarbamoyl prodrug by nitroreductase and NADH. Bioorg. Med. Chem. Lett. 1997, 7, 1065-1070.
25. Atwell, G. J.; Tercel, M.; Boyd, M.; Wilson, W. R.; Denny, W. A. Synthesis and cytotoxicity of 5-amino-l-(chloromethyl)-3- [(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) and related 5-alkylamino analogues: New DNA minor groove alkylating agents. J. Org. Chem. 1998, 63, 9414-9420.
26. Atwell, G. J.; Milbank, J. B. J.; Wilson, W. R.; Hogg, A.; Denny, W. A. 5-Amino-l-(chloromethyl)-1,2-dihydro-3H-benz[e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits. J. Med. Chem. 1999, 42, 3400-3411.
27. Boger, D. L.; Johnson, D. S. CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474.
28. Gieseg, M. A.; Matejovic, J.; Denny, W. A. Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labeled double-stranded DNA. Anti-Cancer Drug Des. 1999, 14, 77-84.
29. Niculescu-Duvaz, I.; Niculescu-Duvaz, D.; Friedlos, F.; Spooner, R.; Martin, J.; Marais, R.; Springer, C. J. Self-immolative anthracycline prodrugs for suicide gene therapy. J. Med. Chem. 1999, 42, 2485-2489.
30. Florent, J. C.; Dong, X.; Gaudel, G.; Mitaku, S.; Monneret, C.; Gesson, J. P.; Jacquesy, J. C.; Mondon, M.; Renoux, B.; Andrianomenjanahary, S.; Michel, S.; Koch, M.; Tillequin, F.; Gerken, M.; Czech, J.; Straub, R.; Bosslet, K. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy. J. Med. Chem. 1998, 41, 3572-3581.
31. Stratford, I. J.; Williamson, C.; Hoe, S.; Adams, G. E. Radiosensitizing and cytotoxicity studies with CB 1954 (2,4-dinitro-5-aziridinylbenzamide). Radiation Research. 1981, 88, 502-509.
32. Teicher, B. A.; Sartorelli, A. C. Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. J. Med. Chem. 1980, 23, 955-960.
33. Denny, W. A.; Wilson, W. R.; Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J. Med. Chem. 1986, 29, 879-887.
34. Palmer, B. D.; Wilson, W. R.; Pullen, S. M.; Denny, W. A. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. J. Med. Chem. 1990, 33, 112-121.
35. Lovering, A. L.; Hyde, E. I.; Searle, P. F.; White, S. A. The structure of Escherichia coli nitroreductase complexed with nicotinic acid: three crystal forms at 1.7, 1.8, 2.4, resolution. J. Miol. Biol. 2001, 309, 203-213.
36. Wilson, W. R.; Pullen, S. M.; Hogg, A.; Hobbs, S. M.; Pruijn, F. B.; Hicks, K. O. In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. In Suicide Gene Therapy: Methods and Protocols for Cancer; Springer, C. J., Ed.; Humana Press: Totowa, New Jersey, 2003, in press.
37. Shiner Jnr, V. J.; Buddenbaum, W. E.; Murr, B. L.; Lamaty, G. Effects of deuterium substitution on the rates of organic reactions. XI. α- and β-Deuterium isotope effects on the solvolysis rates of a series of 1-substituted phenethyl halides. J. Am. Chem. Soc. 1968, 90, 418-426.
38. Finlay, G. J.; Baguley, B. C.; Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem. 1984, 139, 272-277.
39. Palmer, B. D.; Wilson, W. R.; Anderson, R. F.; Boyd, M.; Denny, W. A. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-[N,N-bis(2-chloroethyl)aminol-2,4-dinitrobenzamide. J. Med. Chem. 1996, 39, 2518-2528.